射频消融联合化疗治疗肝转移瘤46例临床分析  

Radiofrequency ablation Combined with Chemotherapy in treatment of Hepatic metastases analysis of 46 cases

作　　者：孔轶[1] 

机构地区：[1]湖南省肿瘤医院肝胆胰内科,湖南长沙410013

出　　处：《大家健康（学术版）》2012年第20期27-31,共5页

摘　　要：目的研究射频消融(RFA)联合化疗治疗肝转移瘤的临床疗效和应用价值。方法选择不能或不愿手术的肝转移瘤患者46例,共110个病灶,先行射频消融治疗后予4～6周期全身化疗,以患者肿瘤灭活率、局部复发率、生存期及1、2、3年总生存率作为评价指标。结果射频消融后一周复查彩色超声多普勒血流显像(CDFI)及CT增强扫描,肿瘤灭活率93.6%。全部病例经6～50个月随访,局部复发率为10%,中位生存期为31个月,而中位无进展生存期为10.9个月,1、2、3年总生存率为86.9%、58.7%、34.8%。结论射频消融联合化疗治疗肝转移瘤疗效好、并发症少,是治疗肝转移瘤安全、有效的综合治疗方法 。Objective the aim of the study was to investigate the clinical effect and application value of percutaneous radiofrequency ablation combined with chemotherapy in treatment of hepatic metastases.Methods the study included 46 patients (totally 110 lesions) with hepatic metastases who did not have the tumors surgically removed.They first had percutaneous radiofrequency ablation treatment,then 4-6 cycle of chemotherapy.Inactivation rate of tumor,local tumor recurrence rate,survival,overall survival at 1st,2nd and 3rd year were used as evaluation endpoint.Results One week after percutaneous radiofrequency ablation,Color Doppler Flow imaging (CDFI) and CT enhancement scanning analysis indicated that inactivation rate of tumor was 93.6%.After 6-50 months follow-up,The local tumor recurrence rates were 10%,the median survival was 31 months;the median progression-free survival was 10.9 months.The overall survival at 1st,2nd and 3rd year were 86.9%、58.7%、34.8%,respectively.Conclusion The treatment combining percutaneous radiofrequency ablation with chemotherapy was effective in therapy of hepatic metastases,with low complication rates.So it is a safe,effective comprehensive treatment for hepatic metastases.

关 键 词：射频消融 化疗 转移性肝肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]